Voyager Therapeutics (VT6) Price & Analysis

5 Followers

VT6 Stock Chart & Stats

€2.61

€0.10(4.16%)

At close: Jul 31 4:00 PM EDT

€2.61

€0.10(4.16%)

Day’s Range― - ―

52-Week Range€1.58 - €4.38

Previous CloseN/A

Volume0.00

Average Volume (3M)25.00

Market Cap

€95.71M

Enterprise Value€128.15M

Total Cash (Recent Filing)€116.34M

Total Debt (Recent Filing)€32.57M

Price to Earnings (P/E)―

Beta0.60

Next Earnings

Nov 10, 2026

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding61,617,947

10 Day Avg. Volume50

30 Day Avg. Volume25

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.18

Price to Sales (P/S)5.71

P/FCF Ratio-1.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.27

Price Target Upside370.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.52

Revenue Forecast (FY)€18.05M

Bulls Say, Bears Say

Bulls Say

Manageable LeverageModerate leverage provides Voyager with a less debt-intensive capital structure than its losses alone would suggest. This limits near-term interest and refinancing pressure, preserving more flexibility to direct available resources toward neurological programs and platform development.

Neuroscience Delivery PlatformVoyager’s focus on engineered AAV capsids and CNS delivery creates a specialized technology foundation across genetic medicines for neurological diseases. Reusable delivery capabilities could support multiple programs and improve the strategic value of successful research over time.

Leadership ContinuityThe planned leadership transition preserves continuity by retaining Sandrock as a board adviser while elevating an internal executive with operational and finance experience. That arrangement may support execution consistency as Voyager advances its Alzheimer’s program and broader pipeline.

Bears Say

Revenue ContractionThe steep, multi-period revenue decline indicates that Voyager’s recent commercial and partnership-related income has not been sustained. A smaller revenue base reduces internal funding capacity, increases dependence on future deals or financing, and makes recovery in operating performance more difficult.

Accelerating Cash BurnThe shift from positive operating cash flow to substantial and accelerating cash burn materially weakens financial flexibility. Persistent outflows can constrain investment in clinical development and increase the importance of obtaining additional capital or other funding sources.

Losses And Shrinking EquityVoyager’s return from profitability to sizable losses is reducing shareholders’ equity and weakening its capital cushion. If this pattern persists, the company may have less capacity to absorb development setbacks, sustain its pipeline, or fund operations without external capital.

Voyager Therapeutics News

Voyager Therapeutic CEO Alfred Sandrock to depart, Robin Swartz to succeed

Voyager Therapeutics (VYGR) announced that its board of directors has appointed Robin Swartz, currently chief business officer and...

4d ago

VYGR

Voyager Therapeutics advances leadership transition amid Alzheimer’s focus

An announcement from Voyager Therapeutics ( ($VYGR) ) is now available. On October 20, 2026, Voyager Therapeutics appointed...

4d ago

VYGR

Voyager Therapeutics: Buy Rating Reiterated as Alzheimer’s Pipeline Advances; $25 Price Target Maintained

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

2M ago

VYGR

Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist

Voyager Therapeutics Inc. ($VYGR) announced an update on their ongoing clinical study. Voyager Therapeutics Inc. is preparing a...

2M ago

VYGR

Voyager Therapeutics Reaffirmed Buy on Advancing Alzheimer’s Pipeline and 4Q26 Tau Program Catalysts; $8 Price Target Maintained

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from...

3M ago

VYGR

Voyager Therapeutics reports Q2 EPS (40c), consensus (51c)

Reports Q2 revenue $3.17M, consensus $4.56M. “We view tau as a critical disease-modifying target in Alzheimer’s disease, and...

3M ago

VYGR

Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

3M ago

VYGR

Voyager Therapeutics advances tau-silencing gene therapy program

Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and...

3M ago

VYGR

Voyager Therapeutics presents six-month toxicology data for VY1706

Voyager Therapeutics (VYGR) presented six-month good laboratory practice toxicology data for VY1706, the company’s investigational gene therapy targeting...

3M ago

VYGR

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

The latest update is out from Voyager Therapeutics ( ($VYGR) ). On June 9, 2026, Voyager Therapeutics, Inc....

5M ago

VYGR

Voyager Therapeutics announces FDA clearance for VY1706 IND application

Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706,...

5M ago

VYGR

Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy

The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1, 2026, Voyager Therapeutics, Inc....

5M ago

VYGR

Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

5M ago

VYGR

Voyager awarded new mission management contract with Exobiosphere

Voyager Technologies and Exobiosphere announced a mission management contract on the International Space Station that marks a concrete...

6M ago

VYGR

VT6 FAQ

What was Voyager Therapeutics’s price range in the past 12 months?

Voyager Therapeutics lowest stock price was €1.58 and its highest was €4.38 in the past 12 months.

What is Voyager Therapeutics’s market cap?

Voyager Therapeutics’s market cap is €95.71M.

When is Voyager Therapeutics’s upcoming earnings report date?

Voyager Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 16 days.

How were Voyager Therapeutics’s earnings last quarter?

Voyager Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.357 earnings per share for the quarter, beating the consensus estimate of -€0.432 by €0.075.

Is Voyager Therapeutics overvalued?

According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics pay dividends?

Voyager Therapeutics does not currently pay dividends.

What is Voyager Therapeutics’s EPS estimate?

Voyager Therapeutics’s EPS estimate is -0.37.

How many shares outstanding does Voyager Therapeutics have?

Voyager Therapeutics has 61,617,947 shares outstanding.

What happened to Voyager Therapeutics’s price movement after its last earnings report?

Voyager Therapeutics reported an EPS of -€0.357 in its last earnings report, beating expectations of -€0.432. Following the earnings report the stock price went up 1.015%.

Which hedge fund is a major shareholder of Voyager Therapeutics?

Currently, no hedge funds are holding shares in DE:VT6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.92%

Trailing 12-Months

Asset Growth

-38.61%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Voyager Therapeutics

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Voyager Therapeutics (VT6) Earnings & Revenues

Historic Earnings Reports

VT6 Stock 12 Month Forecast

Average Price Target

€12.27

▲(370.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","23":"€23","6.5":"€6.5","17.5":"€17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.316766,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.2742213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.14136512,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.5,12,17.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.272,3.813905076923077,5.3558101538461536,6.897715230769231,8.439620307692309,9.981525384615386,11.523430461538462,13.06533553846154,14.607240615384617,16.149145692307695,17.69105076923077,19.232955846153846,20.774860923076922,{"y":22.316766,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.272,3.0414016384615383,3.810803276923077,4.580204915384615,5.349606553846154,6.119008192307692,6.8884098307692305,7.65781146923077,8.427213107692308,9.196614746153847,9.966016384615385,10.735418023076924,11.504819661538463,{"y":12.2742213,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.272,2.6465665476923075,3.021133095384615,3.395699643076923,3.77026619076923,4.144832738461538,4.5193992861538455,4.893965833846153,5.268532381538461,5.643098929230769,6.017665476923076,6.392232024615383,6.766798572307691,{"y":7.14136512,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.758,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.754,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.328,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.264,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.084,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.198,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.174,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.912,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.606,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.832,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.272,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >